HJMC
DNTH icon

Hellman Jordan Management Company’s Dianthus Therapeutics DNTH Stock Holding History

Hellman Jordan Management Company’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$174K Buy
27,570
+16,197
+142% +$287K 0.3% 41
2022
Q3 		$257K Sell
11,373
-7,065
-38% -$193K 0.45% 44
2022
Q2 		$354K Buy
+18,438
New +$456K 0.48% 46

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hellman Jordan Management Company's DNTH Position: Q4 2022 in Review

Hellman Jordan Management Company increased its Dianthus Therapeutics (DNTH) stake by 142% in Q4 2022, buying an estimated $287K and bringing the position to 27,570 shares worth $174K. The position accounts for 0.3% of the portfolio, ranked #41.

Hellman Jordan Management Company first reported a position in DNTH in Q2 2022 and has held it in 3 quarters since. The position peaked at $354K in Q2 2022. 53 funds tracked by Wall St. Rank hold DNTH as of Q4 2022.

  • Hellman Jordan Management Company held 27,570 shares of Dianthus Therapeutics worth $174K as of Q4 2022.
  • Hellman Jordan Management Company bought 16,197 Dianthus Therapeutics shares in Q4 2022, an estimated $287K.
  • Dianthus Therapeutics made up 0.3% of Hellman Jordan Management Company's portfolio in Q4 2022, its #41 holding.
  • Hellman Jordan Management Company first reported a position in Dianthus Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • Hellman Jordan Management Company's Dianthus Therapeutics position peaked at $354K in Q2 2022.
  • 53 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2022.

Based on Hellman Jordan Management Company's 13F filing for Q4 2022, filed 20 Jan 2023.